- What are the key driver mutations that differentiate aggressive from indolent DCIS?
- Are there mutational signatures that differentiate aggressive from indolent DCIS and can these be used to gain more understanding into the biological factors that cause DCIS?
- What are the differences in overall transcriptomic profiles between aggressive and indolent DCIS?
- What are the differences in overall methylation profiles between aggressive and indolent?
- What are the effects of radiotherapy treatment on DCIS?
- Given the wealth of driver and mutational signature data that are already available on primary breast cancers, can we compare DCIS to invasive breast cancers to understand the biology and trajectory of DCIS?
- Can we design integrative predictors of outcome or estimators of biological status that could be informative for optimal treatment based on the data obtained through this endeavour?
- Can we test these hypotheses in prospective DCIS trials going forward?
Dr. Serena Nik-Zainal
CRUK Advanced Clinician Scientist
Academic Department of Medical Genetics
University of Cambridge, Cambridge CB2 0QQ, UK
Prof. Dr. Jacco van Rheenen
Group Leader Division of Molecular Pathology
The Netherlands Cancer Institute, Amsterdam, The Netherlands
Dr Helen Davies
Wellcome Trust Sanger Institute, Hinxton, UK
Professor Ian Tomlinson
Institute of Cancer and Genomic Sciences
University of Birmingham, Birmingham, UK
Workpackage 2 is responsible for the project objective to sequence 1920 DCIS samples.
|2.1||Complete list of drivers and signatures including contributions of each signature to each sample of Phase I samples|
|2.2||Integrative genome profiles per patient of Phase I samples|
|2.3||Sftp site for data sharing up and running|
|2.4||Analysis TCs commence|
|2.5||Sequencing Plan for Phase II|
|2.6||Complete list of drivers and signatures including contributions of each signature to each sample of Phase II sample|
|2.7||Integrative genome profiles per patient of Phase II samples|